additional covid 19 therapy  (Gilead Sciences)

Journal: Diseases

Article Title: A Descriptive, Retrospective Analysis of COVID-19 Passive Antibody Therapy and Its Effects on Morbidity and Mortality in Patients Receiving B-Cell-Depleting Therapies

doi: 10.3390/diseases12020033

Figure Lengend Snippet: Patient characteristics and outcomes in the whole cohort and in two groups, inpatient and outpatient, based on the location of passive antibody therapy administration.

Article Snippet: Hospitalized patients were also more likely to receive additional COVID-19 treatments: 74% of patients received remdesivir, 69% received corticosteroids, and 4% received tocilizumab ( ).

Techniques:

Journal: Transplant Infectious Disease

Article Title: Outcomes of bebtelovimab and sotrovimab treatment of solid organ transplant recipients with mild‐to‐moderate coronavirus disease 2019 during the Omicron epoch

doi: 10.1111/tid.13901

Figure Lengend Snippet: Characteristics of 361 solid organ transplant recipients treated with bebtelovimab or sotrovimab for mild‐to‐moderate coronavirus disease 2019 (COVID‐19)

Article Snippet: Nine admitted patients received additional COVID‐19‐directed therapy, including remdesivir ( N = 7), corticosteroids ( N = 7), and tocilizumab ( N = 1).

Techniques: